drugset / Trial / NCT07561554
Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK42360-Na when given orally in patients with active BRAF V600 mutation locally advanced or metastatic Solid Tumors.
Timeline
- Start
- 2026-03-06
- Primary completion
- 2028-12-02
- Completion
- 2028-12-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSK42360-Na | Unknown | — | Oral |
Indications
No indication recorded.